These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity. Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086 [TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Dosa PI; Covel JA; Ren A; Webb RR; Beeley NR; Martin M; Morgan M; Espitia S; Saldana HR; Bjenning C; Whelan KT; Grottick AJ; Menzaghi F; Thomsen WJ J Med Chem; 2008 Jan; 51(2):305-13. PubMed ID: 18095642 [TBL] [Abstract][Full Text] [Related]
7. Partial agonism, neutral antagonism, and inverse agonism at the human wild-type and constitutively active cholecystokinin-2 receptors. Foucaud M; Tikhonova IG; Langer I; Escrieut C; Dufresne M; Seva C; Maigret B; Fourmy D Mol Pharmacol; 2006 Mar; 69(3):680-90. PubMed ID: 16293711 [TBL] [Abstract][Full Text] [Related]
8. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent. Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852 [TBL] [Abstract][Full Text] [Related]
9. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178 [TBL] [Abstract][Full Text] [Related]
10. A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione, a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity. Szewczyk JR; Laudeman CP; Sammond DM; Villeneuve M; Minick DJ; Grizzle MK; Daniels AJ; Andrews JL; Ignar DM Bioorg Med Chem; 2010 Mar; 18(5):1822-33. PubMed ID: 20172734 [TBL] [Abstract][Full Text] [Related]